Trial Profile
Oral 5-aminosalicylic Acid Withdrawal in Long Standing Inactive Ulcerative Colitis: A Double-blind, Randomized, Placebo-controlled Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2023
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- 30 May 2023 Status changed from recruiting to completed.
- 27 Apr 2020 Planned primary completion date changed from 1 Aug 2019 to 1 Sep 2021.
- 25 Apr 2017 Planned End Date changed from 1 Jul 2018 to 1 Aug 2022.